Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxyphenonium is a synthetic quaternary ammonium anticholinergic (antimuscarinic) agent used to treat or prevent spasms in the muscles of the gastrointestinal tract, such as those seen in irritable bowel syndrome. It is also indicated as an adjunct in the treatment of gastric and duodenal ulcers and for relief of visceral spasms. Oxyphenonium works by blocking muscarinic acetylcholine receptors on smooth muscle, thereby reducing the effect of acetylcholine and directly relaxing smooth muscle tissue. This results in inhibition of gastrointestinal propulsive motility, decreased gastric acid secretion, and control over excessive pharyngeal, tracheal, and bronchial secretions. The drug has also been used topically (as eye drops) to induce mydriasis (pupil dilation)[1][2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oxyphenonium.